Latest Breaking News On - Survival data - Page 1 : comparemela.com

Longeveron Reports Year-End 2023 Results and Provides Corporate Update

Longeveron Reports Year-End 2023 Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMike moyerExchange commissionAmerican heart associationLongeveron incDevelopment expensesLongeveron or companyCompany to hold conference callExchange commission onScientific sessions of the american heart associationReports year endProvides corporatePriorities focusedHypoplastic left heartStudy enrollment anticipatedSurvival data

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBruce mackleAngelos stergiouNational cancer instituteLife sciences reports positiveLife sciences group incMemorial sloan kettering cancer centerBristol myers squibbGenfleet therapeutics shanghai incLifesci advisorsSurvival dataCompleted phaseGalinpepimuts combinedAdvanced malignant pleuralEfficacy metClinical activity

Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update

Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesContactmike moyerlifesci advisorstelDevelopment expensesAmerican heart associationExchange commissionLongeveron incInternational investors dialNational centerLongeveron or companyScientific sessions of the american heart associationJuntendo university hospital tokyoCompany to hold conference callCompany phaseExchange commission onTop line resultsTrial affirm safety profile

Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting?

A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.

Evolving paradigmsCell lung cancerSmall cell lung cancerLimited stage sclcExtensive stage sclcLs sclcEs sclcFirst line treatmentFrontline treatmentFirst line therapyFrontline therapyChemo ioTrio therapyCombination therapyNivo ipiIpi nivo

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Elias jabbourFirst reportComparing ponatinibNewly diagnosedAcute lymphocytic leukemiaCall cancerAll leukemiaPh positiveOph allTyrosine kinase inhibitorsTki therapyCombination therapyBcr ablPonatinib dosePonatinib dosingComplete response